Antithrombins Wibble and Wobble (T85M/K): Archetypal conformational diseases with in vivo latent-transition, thrombosis, and heparin activation

Blood

Volumn 92, Issue 8, 1998, Pages 2696-2706

  Beauchamp, N J ^a   Pike, R N ^a   Daly, M ^a   Butler, L ^a   Makris, M ^a   Dafforn, T R ^a   Zhou, A ^a   Fitton, H L ^a   Preston, F E ^a   Peake, I R ^a   Carrell, R W ^b  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN; HEPARIN; LYSINE; METHIONINE; PENTASACCHARIDE; THREONINE;

ANTITHROMBIN DEFICIENCY; ARTICLE; CLINICAL ARTICLE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; FEMALE; HUMAN; MALE; MUTATION; PEDIGREE ANALYSIS; PRIORITY JOURNAL; THERMOSTABILITY; THROMBOEMBOLISM; THROMBOSIS;

EID: 0032532347     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v92.8.2696     Document Type: Article

References (43)

1. Prusiner SB: Prion diseases and the BSE crisis. Science 278:245, 1997
2. Perutz MF: Glutamine repeats and inherited neurodegenerative diseases: Molecular aspects. Curr Opin Struct Biol 6:848, 1996
3. Yankner BA: Monster plaques: What they tell us about Alzheimer's disease. Nat Med 4:394, 1998
4. Carrell RW, Lomas DA: Conformational diseases. Lancet 350:-134, 1997
5. 1-antitrypsin for structure and function of serpins. Biochemistry 28:8951, 1989
6. Potempa J, Korzus E, Travis J: The serpin family of proteinase inhibitors: Structure function and regulation. J Biol Chem 269:15957, 1994
7. Engh R, Huber R, Bode W, Schulze A: Divining the serpin inhibition mechanism: A suicide substrate 'springe'? Trends Biotech 13:503, 1995
8. Wright HT, Scarsdale JN: Structural basis for serpin inhibitor activity. Proteins 22:210, 1995
9. Stein P, Chothia C: Serpin tertiary structure transformation. J Mol Biol 221:615, 1991
10. Stein PE, Carrell RW: What do dysfunctional serpins tell us about molecular mobility and disease? Nat Struct Biol 2:96, 1995
11. 1-antitrypsin accumulation in the liver. Nature 357:605, 1992
12. Carrell RW, Evans DL, Stein PE: Mobile reactive centre of serpins and the control of thrombosis. Nature 353:576, 1991
13. Bruce D, Perry DJ, Borg J-Y, Carrell RW, Wardell MR: Thromboembolic disease due to thermolabile conformational changes of antithrombin Rouen VI (187 Asn → Asp). J Clin Invest 94:2265, 1994
14. Chang WS, Harper PL: Commercial antithrombin concentrate contains inactive L-forms of antithrombin. Thromb Haemost 77:323, 1997
15. Jin L, Abrahams JP, Skinner R, Petitou M, Pike RN, Carrell RW: The anticoagulant activation of antithrombin by heparin. Proc Natl Acad Sci USA 94:14683, 1997
16. Laurent TC, Tengblad A, Thunberg L, Hook M, Lindahl U: The molecular weight dependence of the anti-coagulant activity of heparin. Biochem J 175:691, 1978
17. Olson ST, Björk I, Shore JD: Kinetic characterization of heparin-catalyzed and uncatalyzed inhibition of blood coagulation proteinases by antithrombin. Methods Enzymol 222:525, 1993
18. Olds RJ, Lane DA, Chowdhury V, De Stefano V, Leone G, Thein SL: Complete nucleotide sequence of the antithrombin gene: Evidence for homologous recombination causing thrombophilia. Biochemistry 32:4216, 1993
19. McKay EJ: A simple two-step procedure for the isolation of antithrombin III from biological fluids. Thromb Res 21:375, 1981
20. Wardell MR, Chang WS, Bruce D, Skinner R, Lesk AM, Carrell RW: Preparative induction and characterization of L-antithrombin: A structural homologue of latent plasminogen activator inhibitor-1. Biochemistry 36:13133, 1997
21. 1-antitrypsin. J Biol Chem 270:5282, 1995
22. Lawrence DA, Olson ST, Palaniappan S, Ginsburg D: Engineering plasminogen activator inhibitor 1 mutants with increased functional stability. Biochemistry 33:3643, 1994
23. Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680, 1970
24. Goldenberg DP: Analysis of protein conformation by gel electrophoresis, in Creighton TE (ed): Protein Structure: A Practical Approach. Oxford, UK, IRL, 1989, p 225
25. Towbin H, Staehelin T, Gordon J: Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: Procedure and applications. Proc Natl Acad Sci USA 76:4350, 1979
26. 2-antiplasmin, angiotensinogen, and ovalbumin. Biochemistry 30:1723, 1991
27. Laurell CB: Electroimmunoassay. Scand J Clin Lab Invest 125:21, 1972
28. Schagger H, Von Jagow G: Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the separation of proteins in the range from 1 to 100 kDa. Anal Biochem 166:368, 1987
29. Matsudaira P: Sequence from picomole quantities of proteins electroblotted onto polvinylidene difluoride membranes. J Biol Chem 262:10035, 1987
30. Olson ST, Björk I, Sheffer R, Craig PA, Shore JD, Choay J: Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions. Resolution of the antithrombin conformational change contribution to heparin rate enhancement. J Biol Chem 267:12528, 1992
31. Beauchamp NJ, Daly ME, Cooper PC, Makris M, Preston FE, Peake IR: Molecular basis of protein S deficiency in three families also showing independent inheritance of factor V Leiden. Blood 88:1700, 1996
32. Creagh MD, Roberts IF, Clark DJ, Preston FE: Familial antithrombin III deficiency and Mycolplasma pneumoniae pneumonia. J Clin Pathol 44:870, 1991
33. Lane DA, Bayston T, Olds RJ, Fitches AC, Cooper DN, Millar DS, Jochmans K, Perry DJ, Okajima K, Thein SL, Emmerich J: Antithrombin Mutation Database: 2nd (1997) Update. For the Plasma Coagulation Inhibitors Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 77:197, 1997
34. Huntington JA, Olson ST, Fan B, Gettins PGW: Mechanism of heparin activation of antithrombin. Evidence for reactive loop preinsertion with expulsion on heparin binding. Biochemistry 35:8495, 1996
35. 1-antitrypsin deficiency. Scand J Clin Lab Invest 15:132, 1963
36. Lee KN, Im H, Kang SW, Yu M-H: Characterization of a human α1-antitrypsin variant that is as stable as ovalbumin. J Biol Chem 273:2509, 1998
37. Mottonen J, Strand A, Symersky J, Sweet RM, Danley DE, Geoghegan KF, Gerard RD, Goldsmith EJ: Structural basis of latency in plasminogen activator inhibitor-1. Nature 355:270, 1992
38. Chang W-SW, Lomas DA: Latent α1-antichymotrypsin. A molecular explanation for the inactivation of α1-antichymotrypsin in chronic bronchitis and emphysema. J Biol Chem 273:3695, 1997
39. Skinner R, Abrahams JP, Whisstock JC, Lesk AM, Carrell RW, Wardell MR: The 2.6Å structure of antithrombin indicates a conformational change at the heparin binding site. J Mol Biol 266:601, 1997
40. Pike RN, Potempa J, Skinner R, Fitton HL, McGraw WT, Travis J, Owen M, Jin L, Carrell RW: Heparin-dependent modification of the reactive center arginine of antithrombin and consequent increase in heparin binding affinity. J Biol Chem 272:19652, 1997
41. Huntington JA, Gettins PGW: Conformational conversion of antithrombin to a fully activated substrate of factor Xa without need for heparin. Biochemistry 37:3272, 1998
42. Carrell RW, Stein PE, Fermi G, Wardell MR: Biological implications of a 3Å structure of dimeric antithrombin. Structure 2:257, 1994
43. 1-antitrypsin. Nat Struct Biol 3:676, 1996